Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Periprosthetic osteolysis: an immunologist's update.

Looney RJ, Schwarz EM, Boyd A, O'Keefe RJ.

Curr Opin Rheumatol. 2006 Jan;18(1):80-7. Review.

PMID:
16344623
2.

Emerging ideas: Instability-induced periprosthetic osteolysis is not dependent on the fibrous tissue interface.

Nam D, Bostrom MP, Fahlgren A.

Clin Orthop Relat Res. 2013 Jun;471(6):1758-62. doi: 10.1007/s11999-013-2896-8. Epub 2013 Mar 6.

3.

Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty.

Wang CT, Lin YT, Chiang BL, Lee SS, Hou SM.

Biomaterials. 2010 Jan;31(1):77-82. doi: 10.1016/j.biomaterials.2009.09.017. Epub 2009 Sep 25.

PMID:
19781765
4.

Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.

Noordin S, Masri B.

Can J Surg. 2012 Dec;55(6):408-17. doi: 10.1503/cjs.003711. Review.

5.

RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.

Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ.

J Musculoskelet Neuronal Interact. 2004 Sep;4(3):276-84. Review.

6.

What potential biologic treatments are available for osteolysis?

Schwarz EM; Implant Wear Symposium 2007 Biologic Work Group.

J Am Acad Orthop Surg. 2008;16 Suppl 1:S72-5.

PMID:
18612019
7.

NFkappaB gene silencing inhibits wear particles-induced inflammatory osteolysis.

Cheng T, Zhang X.

Med Hypotheses. 2008 Nov;71(5):727-9. doi: 10.1016/j.mehy.2008.07.003. Epub 2008 Aug 15.

PMID:
18707816
8.

Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.

Gehrke T, Sers C, Morawietz L, Fernahl G, Neidel J, Frommelt L, Krenn V.

Scand J Rheumatol. 2003;32(5):287-94.

PMID:
14690142
9.

Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directions.

Beck RT, Illingworth KD, Saleh KJ.

J Orthop Res. 2012 Apr;30(4):541-6. doi: 10.1002/jor.21554. Epub 2011 Sep 15. Review.

10.

Is there another possible approach to inhibit wear particles-induced inflammatory osteolysis?

Liu YP, Yu GR, Li K, Yuan F.

Med Hypotheses. 2011 Feb;76(2):280-2. doi: 10.1016/j.mehy.2010.10.023. Epub 2010 Nov 9.

PMID:
21067868
11.

What are the guidelines for the surgical and nonsurgical treatment of periprosthetic osteolysis?

Stulberg BN, Della Valle AG; Implant Wear Symposium 2007 Clinical Work Group.

J Am Acad Orthop Surg. 2008;16 Suppl 1:S20-5.

PMID:
18612009
12.

The role of macrophages in osteolysis of total joint replacement.

Ingham E, Fisher J.

Biomaterials. 2005 Apr;26(11):1271-86. Review.

PMID:
15475057
13.
14.

Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies.

Abu-Amer Y, Darwech I, Clohisy JC.

Arthritis Res Ther. 2007;9 Suppl 1:S6. Review.

15.

The cellular and molecular biology of periprosthetic osteolysis.

Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP.

Clin Orthop Relat Res. 2007 Jan;454:251-61. Review.

PMID:
16980902
16.

Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.

Schwarz EM, Looney RJ, O'Keefe RJ.

Arthritis Res. 2000;2(3):165-8. Epub 2000 Mar 27. Review.

17.
18.

Particle disease. A comprehensive theory of periprosthetic osteolysis: a review.

Gallo J, Kamínek P, Tichá V, Riháková P, Ditmar R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2002 Dec;146(2):21-8. Review.

19.

Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model.

Ren W, Wu B, Peng X, Mayton L, Yu D, Ren J, Chen BD, Wooley PH.

J Orthop Res. 2006 Feb;24(2):280-90.

20.

The role of the macrophage in periprosthetic bone loss.

Santerre JP, Labow RS, Boynton EL.

Can J Surg. 2000 Jun;43(3):173-9. Review.

Supplemental Content

Support Center